Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802)

詳細情報 詳細情報について

• CRID

  1360855571460671744

• DOI

  10.1093/annonc/mdv276

• ISSN

  09237534

• Web Site

  https://api.elsevier.com/content/article/PII:S0923753419317764?httpAccept=text/xml

  https://api.elsevier.com/content/article/PII:S0923753419317764?httpAccept=text/plain

  http://academic.oup.com/annonc/article-pdf/26/9/1877/467925/mdv276.pdf

• データソース種別

  • Crossref